Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive and Lymph Node Negative Invasive Breast Cancer

NCT05841381 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05841381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05841381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive and Lymph Node Negative Invasive Breast Cancer
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
May 6, 2023
Completion date
May 6, 2033
Enrollment
876 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer